argenx (NASDAQ:ARGX) Price Target Raised to $803.00

argenx (NASDAQ:ARGX) had its price objective lifted by Citigroup from $796.00 to $803.00 in a report published on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Robert W. Baird boosted their target price on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. JMP Securities raised their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. Finally, Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a research note on Monday, March 17th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $697.94.

argenx Stock Down 3.4%

Shares of argenx stock opened at $549.65 on Friday. The business has a 50-day moving average price of $596.27 and a 200 day moving average price of $613.81. argenx has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The firm has a market cap of $33.56 billion, a P/E ratio of -624.60 and a beta of 0.57.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities research analysts anticipate that argenx will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Fulton Bank N.A. acquired a new stake in argenx in the fourth quarter worth about $226,000. Assenagon Asset Management S.A. raised its position in shares of argenx by 21.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company’s stock worth $21,497,000 after buying an additional 6,161 shares in the last quarter. Park Avenue Securities LLC lifted its stake in shares of argenx by 40.0% in the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company’s stock worth $1,042,000 after acquiring an additional 484 shares during the period. Ritholtz Wealth Management boosted its holdings in shares of argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after acquiring an additional 414 shares in the last quarter. Finally, Aaron Wealth Advisors LLC increased its stake in shares of argenx by 10.1% during the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $301,000 after acquiring an additional 45 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.